Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Total Valuation
Kezar Life Sciences has a market cap or net worth of $32.88M. The enterprise value is -$67.01M.
Market Cap$32.88M
Enterprise Value-$67.01M
Share Statistics
Kezar Life Sciences has 7,305,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,305,800
Owned by Insiders19.67%
Owned by Institutions42.62%
Financial Efficiency
Kezar Life Sciences’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -66.32%.
Return on Equity (ROE)-0.72
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-66.32%
Return on Capital Employed (ROCE)-0.73
Revenue Per Employee0.00
Profits Per Employee-1.52M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kezar Life Sciences is -5.85. Kezar Life Sciences’s PEG ratio is 0.33.
PE Ratio-5.85
PS Ratio6.14
PB Ratio4.19
Price to Fair Value4.19
Price to FCF-6.60
Price to Operating Cash Flow-6.60
PEG Ratio0.33
Income Statement
In the last 12 months, Kezar Life Sciences had revenue of 0.00 and earned -83.74M in profits. Earnings per share was -1.15.
Revenue0.00
Gross Profit0.00
Operating Income-90.61M
Pretax Income-83.74M
Net Income-83.74M
EBITDA-90.61M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was -74.21M and capital expenditures -29.00K, giving a free cash flow of -74.24M billion.
Operating Cash Flow-74.21M
Free Cash Flow-74.24M
Free Cash Flow per Share-10.16
Dividends & Yields
Kezar Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-42.82%
50-Day Moving Average5.34
200-Day Moving Average6.36
Relative Strength Index (RSI)45.62
Average Volume (3m)26.05K
Important Dates
Kezar Life Sciences upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateMar 25, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Kezar Life Sciences as a current ratio of 6.76, with Debt / Equity ratio of 13.84%
Current Ratio6.76
Quick Ratio6.76
Debt to Market Cap0.02
Net Debt to EBITDA0.34
Interest Coverage Ratio56.88
Taxes
In the past 12 months, Kezar Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kezar Life Sciences EV to EBITDA ratio is -5.07, with an EV/FCF ratio of -6.19.
EV to Sales0.00
EV to EBITDA-5.07
EV to Free Cash Flow-6.19
EV to Operating Cash Flow-6.19
Balance Sheet
Kezar Life Sciences has $132.25M in cash and marketable securities with $16.18M in debt, giving a net cash position of -$116.06M billion.
Cash & Marketable Securities$132.25M
Total Debt$16.18M
Net Cash-$116.06M
Net Cash Per Share-$15.89
Tangible Book Value Per Share$1.60
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kezar Life Sciences is $12.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$12.50
Price Target Upside172.93% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast18.17%